X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with IT PEOPLE (INDIA) - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs COMMEX TECHNOLOGY - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES COMMEX TECHNOLOGY INDOCO REMEDIES/
COMMEX TECHNOLOGY
 
P/E (TTM) x 30.7 -0.2 - View Chart
P/BV x 3.6 0.1 3,517.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 INDOCO REMEDIES   COMMEX TECHNOLOGY
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
COMMEX TECHNOLOGY
Mar-14
INDOCO REMEDIES/
COMMEX TECHNOLOGY
5-Yr Chart
Click to enlarge
High Rs36030 1,213.5%   
Low Rs24911 2,350.0%   
Sales per share (Unadj.) Rs119.01.7 7,194.3%  
Earnings per share (Unadj.) Rs8.40.1 7,488.2%  
Cash flow per share (Unadj.) Rs15.20.3 4,923.5%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.78.1 872.3%  
Shares outstanding (eoy) m92.15147.73 62.4%   
Bonus/Rights/Conversions -GDR-  
Price / Sales ratio x2.612.2 21.0%   
Avg P/E ratio x36.4180.4 20.2%  
P/CF ratio (eoy) x20.065.1 30.7%  
Price / Book Value ratio x4.32.5 173.4%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,0832,977 943.4%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,16797 2,231.4%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,968244 4,487.6%  
Other income Rs m4011 374.5%   
Total revenues Rs m11,007255 4,316.6%   
Gross profit Rs m1,56545 3,461.5%  
Depreciation Rs m63329 2,167.1%   
Interest Rs m620 20,700.0%   
Profit before tax Rs m90926 3,457.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m13910 1,415.3%   
Profit after tax Rs m77117 4,670.9%  
Gross profit margin %14.318.5 77.1%  
Effective tax rate %15.337.3 40.9%   
Net profit margin %7.06.8 104.1%  
BALANCE SHEET DATA
Current assets Rs m5,725589 972.3%   
Current liabilities Rs m5,454132 4,135.0%   
Net working cap to sales %2.5186.9 1.3%  
Current ratio x1.04.5 23.5%  
Inventory Days Days620-  
Debtors Days Days72161 44.6%  
Net fixed assets Rs m5,307440 1,205.1%   
Share capital Rs m184310 59.4%   
"Free" reserves Rs m6,331859 736.8%   
Net worth Rs m6,5161,197 544.1%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9701,329 900.4%  
Interest coverage x15.688.7 17.6%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.2 498.4%   
Return on assets %7.01.3 550.5%  
Return on equity %11.81.4 858.4%  
Return on capital %12.42.2 557.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886-117 -760.9%  
From Investments Rs m-1,706141 -1,211.3%  
From Financial Activity Rs m1,316-26 -4,983.7%  
Net Cashflow Rs m497-2 -22,572.7%  

Share Holding

Indian Promoters % 59.2 38.4 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.0 62,500.0%  
FIIs % 6.0 21.5 27.9%  
ADR/GDR % 0.0 4.8 -  
Free float % 22.4 35.4 63.3%  
Shareholders   12,805 20,783 61.6%  
Pledged promoter(s) holding % 0.0 75.2 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   NESCO LIMITED  TIL LTD  BAJAJ FINANCE  STC INDIA  CCL INTERNATIONAL  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Feb 20, 2018 11:29 AM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - INDIABULLS FIN. SER. COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS